X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
The study was conducted by an independent contract research organization to evaluate the in vitro bactericidal properties of R327 against C. perfringens and S. pyogenes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Brandon Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
Details:
The new financing will advance INNA-051, ENA Respiratory’s lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
